A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

NCT00851734 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG: voclosporin ophthalmic solution

Sponsor

Lux Biosciences, Inc.